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Abstract
Background: The role of the neurotrophin regulated polypeptide, VGF, has been investigated in
a rat spared injury model of neuropathic pain. This peptide has been shown to be associated with
synaptic strengthening and learning in the hippocampus and while it is known that VGFmRNA is
upregulated in dorsal root ganglia following peripheral nerve injury, the role of this VGF peptide in
neuropathic pain has yet to be investigated.
Results: Prolonged upregulation of VGF mRNA and protein was observed in injured dorsal root
ganglion neurons, central terminals and their target dorsal horn neurons. Intrathecal application of
TLQP-62, the C-terminal active portion of VGF (5–50 nmol) to naïve rats caused a long-lasting
mechanical and cold behavioral allodynia. Direct actions of 50 nM TLQP-62 upon dorsal horn
neuron excitability was demonstrated in whole cell patch recordings in spinal cord slices and in
receptive field analysis in intact, anesthetized rats where significant actions of VGF were upon
spontaneous activity and cold evoked responses.
Conclusion: VGF expression is therefore highly modulated in nociceptive pathways following
peripheral nerve injury and can cause dorsal horn cell excitation and behavioral hypersensitivity in
naïve animals. Together the results point to a novel and powerful role for VGF in neuropathic pain.
Background
The spontaneous burning pain, hyperalgesia and allody-
nia that characterize neuropathic pain are triggered and
maintained by a combination of peripheral and central
processes [1,2]. Peripheral mechanisms include the onset
of ectopic activity in the injured sensory neurons, cross
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talk between sensory and sympathetic neurons and inter-
action with peripheral immune cells [3], while central
mechanisms include central sensitization through mem-
brane depolarization and homo and heterosynaptic
potentiation maintained by loss of inhibition and
immune activation [4-6].
At the heart of many of these processes lie the neuro-
trophins, which in addition to controlling the survival
and differentiation of neurons, play a key role in main-
taining and modulating the function of adult nociceptive
neurons. NGF and BDNF are highly regulated in skin,
peripheral and central neurons, and glia following nerve
injury and tissue inflammation, and have been repeatedly
implicated in the development and maintenance of
chronic neuropathic pain states [7-10].
Microarray analysis of dorsal root ganglia (DRG) mRNA
following experimental nerve injury has revealed a strik-
ing upregulation of another gene regulated by neuro-
trophins, VGF [11,12]. VGF polypeptide is found in a
distinctive restricted cell distribution in the adult brain,
peripheral nervous system, and neuroendocrine system,
where it is sorted into secretory granules, processed into
small peptides by endoproteolytic cleavage, and released
upon depolarization [13]. VGF is notable for its rapid and
strong regulation by NGF and BDNF, which drive vgf gene
transcription in vitro and in vivo, increasing VGF mRNA
levels up to 50-fold in PC12 cells [13,14]. More recently,
VGF regulation has been associated with synaptic
strengthening and learning in the hippocampus [15] and
to act downstream of BDNF to increase cell division in the
hippocampus and counteract depression in animal mod-
els [16]. Despite the reported regulation of VGF mRNA by
peripheral nerve injury, it is not known if VGF plays a role
in neuropathic pain.
Here we report that VGF is upregulated in both DRG and
dorsal horn neurons in a model of neuropathic pain and
show that VGF peptide application to the naïve spinal
cord directly influences dorsal horn neuron excitability
and induces typical neuropathic behavior.
Results
Pattern of VGF mRNA and protein upregulation in DRG 
neurons following spared nerve injury
We used the hindlimb spared nerve injury (SNI) model of
neuropathic pain to examine the dynamic regulation of
VGF in primary sensory neurons in the rat L4/L5 dorsal
root ganglia (DRG). Figure 1A shows that SNI triggers a
sustained 3 fold upregulation of VGF mRNA that is main-
tained for at least 3 weeks. In situ hybridization (Figure
1B) shows that this upregulation is restricted to DRG neu-
rons; no VGF mRNA expression is observed in glial or sat-
ellite cells. The number of neurons expressing VGF mRNA
increases steadily post injury with a time course that par-
allels the qPCR data. Quantification of the in situ hybridi-
zation shows that both the amount of VGF mRNA per cell
and the number of cells expressing VGF mRNA is signifi-
cantly greater in the ipsilateral compared to the contralat-
eral DRG at 7 and 21 days post injury (Figure 1C & D).
VGF protein is also upregulated in the L4 and L5 DRG fol-
lowing SNI. Figure 2A shows the low level of VGF immu-
noreactivity in naïve L4 DRG compared to the ipsilateral
L4 DRG 7 days following SNI in figure 2B. Increased VGF
expression was observed in both large and small diameter
DRG neurons and staining was cytoplasmic and punctate
in nature, consistent with its storage in secretory vesicles
(Levi et al., 2004). Figure 2C shows that by day 21 post
injury there is a 20 fold increase in VGF positive cells in
the ipsilateral relative to contralateral DRG. To establish
whether the VGF upregulation was in neurons whose
axons were damaged by SNI surgery, we applied a retro-
grade tracer (True blue) to the cut end of the peripheral
nerves at the time of the injury. Figure 2D shows that
increased VGF expression in ipsilateral L4 DRG 7 days
post injury is largely, but not entirely restricted to injured
neurons.
Taken together these data clearly show strong upregula-
tion of VGF mRNA and protein in injured DRG neurons
following nerve injury.
Pattern of VGF mRNA and protein upregulation in dorsal 
horn neurons following spared nerve injury
VGF mRNA and protein is also increased in the L4/L5 dor-
sal horn after SNI. Figure 1D shows the significant mean
fold increase in mRNA in the ipsilateral L4/5 dorsal horn
at 3 and 7 days post injury. In situ hybridization revealed
that the pattern of mRNA upregulation is not uniform
across the dorsal horn. It appears that mRNA increased in
neurons in the superficial laminae and in deeper lamina
IV-V, while neurons in inner lamina II-III remained rela-
tively unaffected (Figure 1E) although this requires further
quantitation.
A similar pattern of upregulation of VGF protein expres-
sion is observed in the dorsal horn (Figure 3A–D). In the
naïve L4 spinal cord (Figure 3A), both neurons and termi-
nals are immunolabelled with VGF. Neuronal VGF is
largely restricted to scattered neurons in laminae III-IV
and the ventral horn and light terminal labeling is
observed around the central canal and lamina I and II.
These terminals partly arise from primary afferents as
shown by the decrease following dorsal rhizotomy and
partly from descending axons in the dorsolateral funicu-
lus (DLF) as shown by DLF lesions and co-labelling of
back-labelled descending projection neurones and VGF in
the brainstem (Additional file 1). Some VGF staining isMolecular Pain 2008, 4:62 http://www.molecularpain.com/content/4/1/62
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Increased VGF mRNA expression in L4/5 DRG and dorsal horn following SNI Figure 1
Increased VGF mRNA expression in L4/5 DRG and dorsal horn following SNI. A. QPCR analysis of VGF mRNA in 
ipsilateral L4/5 DRG from naïve and 3, 7 and 21 days post-SNI. Data is expressed as the mean fold change ± standard deviation 
normalised to naïve values (* p ≤ 0.05, ANOVA, n = 8 per group). B In situ hybridization histochemistry of L4/5 DRG showing 
the change in VGF mRNA expression post-injury. C Quantification of in situ hybridization data showing the mean number of 
ipsilateral and contralateral DRG cells expressing VGF mRNA and the mean density of silver grains at 7 and 21 days post-SNI 
(* p ≤ 0.05, ANOVA, Dunnetts post-hoc test, n = 4 per group). D. QPCR analysis of VGF mRNA from L4/5 naïve and ipsilateral 
dorsal horn quadrants, 3, 7 and 21 days post-SNI. Data is expressed as the mean fold change ± standard deviation and normal-
ised to naïve values (*p ≤ 0.05, ANOVA, n = 8 per group). E. In situ hybridization of VGF mRNA in L4/5 spinal cord at 7 days 
post-SNI.
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likely also to arise from the terminals of spinal interneu-
rons. The VGF primary afferent terminal labeling overlaps
with CGRP+ve (Figure 3E) but not IB4+ve (Figure 3F) pri-
mary afferents in the superficial dorsal horn.
Seven and 21 days after SNI there is a substantial increase
in terminal labeling in superficial laminae and a more dif-
fuse upregulation in terminals in laminae III-V (Figure 3B
& C). This increased terminal labeling is restricted to the
somatotopic region of termination of the affected affer-
ents in the L4 and L5 segments (Figure 3D). In addition,
VGF protein is upregulated in intrinsic neurons in both
superficial and deep laminae following nerve injury. The
number of VGF-labelled cells in laminae II-V on the ipsi-
lateral side was more than 3 times greater than the contral-
ateral side at 7 days post injury (ipsi: 21.8 ± 1.6, contra:
6.6 ± 0.6 cells/section, n = 14 sections from 4 animals).
Double labeling with specific neuronal, microglial and
astrocytic markers confirmed that the VGF protein in post
Increased VGF protein expression in L4/5 DRG following SNI Figure 2
Increased VGF protein expression in L4/5 DRG following SNI. A. VGF protein immunostaining in naive L4 DRG shows 
very low basal levels compared to B. 7 days following SNI where a significant increase in the expression of VGF in all diameter 
cell bodies can be seen. Inset shows detail of punctuate cytoplasmic VGF staining. C. The mean number of cells/section 
expressing VGF in the ipsilateral and contralateral L4 DRG, 21 days post SNI highlights this increase in ipsilateral labeling for 
VGF (* p ≤ 0.05, t-test, n = 3 per group). D. Retrograde labelling of injured cell bodies (red) shows VGF expression is largely 
found in both large and small injured cell bodies (orange, arrows), although expression is also visible in uninjured/untraced 
DRG cell bodies (arrow). Scale bars 50 μm.
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Immunohistochemistry of VGF in the spinal cord of (A) naïve and (B) nerve injured rats at 7 days and (C) 21 days post-SNI Figure 3
Immunohistochemistry of VGF in the spinal cord of (A) naïve and (B) nerve injured rats at 7 days and (C) 21 days post-SNI. 
Arrows show increased VGF staining in the C fibre terminal region of the ipsilateral superficial laminae (LI-II), intrinsic dorsal 
horn neurons throughout the dorsal horn and ventral horn neurons (n = 4 per group). D. Increased VGF expression in the 
central afferent terminals (arrow) coincides with afferent IB4 depletion following SNI. (Scale bars: 100 μm). E. Double immu-
nolabeling of naïve (uninjured) spinal cord sections shows colocalisation in terminals (yellow, arrow) of VGF (green) and CGRP 
(red) a marker of peptidergic C-fibres. F. Double immunolabeling of naïve uninjured spinal cord sections shows little overlap in 
VGF (green, arrow) and IB4 (red), a marker of non-peptidergic C-fibres (Scale bars: 50 μm).
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injury dorsal horn was restricted to neurons (Additional
file 2).
Taken together these data show strong and selective
upregulation of VGF mRNA and protein in dorsal horn
neurons and terminals following nerve injury.
Spinal VGF application causes behavioral mechanical and 
cold hypersensitivity
Since VGF is highly regulated in the DRG and dorsal horn
following peripheral nerve injury, we hypothesized that it
may have a role in the behavioral hypersensitivity to
touch and cold that is a characteristic of neuropathic pain.
We therefore investigated the effects of acute intrathecal
application of TLQP-62 (the C-terminal 62 amino acid
VGF-derived peptide) upon hindlimb flexion withdrawal
in response to the application of acetone and to graded
mechanical stimulation of the hindpaw.
Figure 4A shows the increased paw sensitivity to cutane-
ous acetone cooling following L4/5 intrathecal applica-
tion of 25 and 50 nmol TLQP-62. This is an innocuous
cooling stimulus that causes very little response in control
animals but both 25 and 50 nmol TLQP-62 cause a signif-
icant increase in the paw withdrawal response to cooling
compared to saline (P < 0.001, ANOVA). The effect is pro-
longed, a single intrathecal injection lasting for nearly 2
hours. A dose response relationship can be observed in
the Fig 4A, although this was not significant.
Fig 4B shows the increased paw sensitivity to cutaneous
mechanical stimulation with von Frey hairs following 25
and 50 nmol TLQP-62. Both doses cause a significant
decrease in the paw withdrawal thresholds compared to
saline (P < 0.05 and 0.001, ANOVA). Again the effect is
prolonged, the response to a single intrathecal injection
lasting for 3 hours. A dose response trend in the duration
of the effect can be observed in Fig 3B, although this was
not significant.
Together these data show that VGF, applied directly to the
spinal cord, causes comparable mechanical and cooling
hypersensitivity in naïve animals to that reported follow-
ing nerve injury.
VGF influences the excitability of dorsal horn neurons
To test whether the behavioural hypersensivity following
intrathecal VGF is due to changes in dorsal horn neuronal
excitability we investigated the effects of acute application
of the C-terminal VGF-derived peptide TLQP-62 upon the
activity of single superficial dorsal horn neurons in rat spi-
nal cord slices from naïve animals. The frequency of spon-
taneous excitatory post synaptic currents (sEPSC) was
significantly altered by bath application of 50 nM TLQP-
62 in the majority (82%, n = 11) of cells examined (Figure
5). Of these cells most (70%) were excited, with a 2-fold
increase in the mean sEPSC frequency (Figure 5B). A pro-
portion of cells (30%) were inhibited by TLQP-62 and
displayed a 50% decrease in sEPSC frequency (Figure 5B).
The peak effect of TLQP-62 was observed after 5–10 min-
utes of application and in all but one cell, firing had
returned to baseline levels after 30 minutes of wash out in
normal aCSF
The effect of VGF peptide was also tested on dorsal horn
cells in vivo in naïve isoflurane anaesthetized rats in pro-
longed extracellular recordings of single wide dynamic
range neurons in laminae III-V (Figure 6). Neuronal activ-
ity was analysed every ten minutes before and for up to
100 minutes after application of TLQP-62 (50 nM). In the
majority of neurons (77%, n = 14) spontaneous firing sig-
nificantly increased and in a subpopulation of cells (n =
4) strikingly so (Figure 6A & B). In a smaller population
of cells (15%) the spontaneous firing was decreased and
the remainder was unchanged. The effect of TLQP-62 was
also tested on the activity evoked by stimulating cutane-
ous receptive fields (Figure 6C). Application of TLPQ-62
significantly increased the mean response to brushing and
cooling the receptive field while leaving pinch responses
unaffected. The most striking effect was to acetone appli-
cation, which in this cell population had no effect at base-
line. Application of TLQP-62 led to a strong cooling
response in 70% of cells and again the effect was intense
in a subpopulation (n = 4) (Figure 6C).
These results show that VGF can directly influence sponta-
neous and evoked responses of activity of naïve dorsal
horn cells.
Discussion
The results show that the polypeptide VGF is strongly
upregulated in injured DRG neurons and their central tar-
get dorsal horn neurons following SNI.
The onset and maintenance of this upregulation mirrors
the time course of behavioral allodynia that is a feature of
this animal model of neuropathic pain [17]. The baseline
distribution and cellular location of VGF peptide in neu-
rons, but not glial cells is consistent with earlier studies
describing the distribution of this peptide in the brain
[18,19,13]. Identification of VGF receptors will allow fur-
ther insight into its neuronal and glial targets.
The striking upregulation of VGF in sensory neurons fol-
lowing nerve injury is reminiscent of the selective and
maintained activation of VGF in other brain regions in
response to neurotropins and prolonged neuronal depo-
larization [13,15,14] and is likely to result from injury
induced spike activity and neurotrophin upregulation in
the DRG and dorsal horn. Peripheral nerve damage trig-Molecular Pain 2008, 4:62 http://www.molecularpain.com/content/4/1/62
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The effects of intrathecal TLQP-62 and saline vehicle on reflex withdrawal responses to innocuous cold and mechanical stimuli  in naive rats Figure 4
The effects of intrathecal TLQP-62 and saline vehicle on reflex withdrawal responses to innocuous cold and mechanical stimuli 
in naive rats. A. Mean suspended paw elevation time in seconds to acetone applied to the hind paw B. Mean paw withdrawal 
threshold (g) to mechanical von Frey hair stimulation after intrathecal administration of TLQP-62. Each point is the mean of 8 
rats.
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TLQP-62 alters the spontaneous excitability of superficial dorsal horn neurones Figure 5
TLQP-62 alters the spontaneous excitability of superficial dorsal horn neurones. sEPSCs were recorded in lamina I and II neu-
rones from P21 spinal cord slices using whole cell patch clamp techniques. Cells were clearly divided in their response to 
TLQP-62 (50 nM) with 6/9 neurones showing a significant increase in the frequency of sEPSCs while 3/9 cells were significantly 
inhibited, as illustrated by sample traces (A) and histograms showing the normalised frequency of spontaneous activity before 
and 10 minutes after TLQP-62 application (B). The effects were classified as inhibitory or excitatory using a Komologorov-
Smirnov 2-sample test (P < 0.05) and a t-test was used to compare the population data in B (*P < 0.05).
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The effect of spinal TLQP-62 (50 nM) application upon L4/L5 dorsal horn cell activity in intact anaesthetized rats Figure 6
The effect of spinal TLQP-62 (50 nM) application upon L4/L5 dorsal horn cell activity in intact anaesthetized rats. A & B. A dor-
sal horn cell that had very little spontaneous spike activity at baseline, developed very high frequency spontaneous firing, shown 
here 50 mins post TLQP-62. C. The effect of spinal TLQP-62 application upon spontaneous activity in individual dorsal horn 
cells. The number of action potentials over a 10 min period is shown at baseline and at 75 mins post TLQP-62. The logarithmic 
scale reflects the very intense effect of TLQP-62 in a subpopulation of cells. D. The effect of spinal TLQP-62 upon brush, pinch 
and acetone evoked activity in dorsal horn cells (n = 14). The mean number of action potentials evoked by each stimulus (dura-
tion 1.5 secs) is shown at baseline and at 75 mins post TLQP-62. *P < 0.05, **P < 0.001 ; Mann-Whitney U test).
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gers NGF release by macrophages, mast cells and Schwann
cells, [10] and BDNF upregulation in trkA expressing DRG
cells. Anti-NGF treatment leads to reduction of allodynia
in peripheral nerve injury models [10] and many of the
injury induced changes in dorsal horn neuronal excitabil-
ity are mediated by release of BDNF from microglia [7]. It
is possible that these effects are mediated via VGF or select
VGF-derived peptides. The colocalization of VGF with
peptidergic primary afferents, in agreement with previous
reports in culture [10], suggests depolarisation and neuro-
trophin mediated VGF release from a select group of noci-
ceptors.
VGF application in naive animals had striking behav-
ioural effects that mirror those of neuropathic pain; an
allodynic response to cooling and mechanical stimulation
are major features of this type of chronic pain [1]. Our
results show that VGF acts, at least in part, by selective
changes in the excitability of subpopulations of dorsal
horn cells. While mixed responses are likely to reflect the
presence of both excitatory and inhibitory neurons, the
overall effect of VGF peptide was to increase global dorsal
horn network activity, analogous to BDNF [20]. This was
supported by the in vivo receptive field analysis which
showed that VGF peptide significantly increased sponta-
neous activity and evoked responses to cooling.
Conclusion
In conclusion we identify a neuropeptide that has pro-
found functional effects on dorsal horn neurons and sen-
sory behavior. Taken together with its upregulation in
primary sensory and dorsal horn neurons in response to
peripheral nerve injury, these data suggest that VGF has a
central mechanistic role in neuropathic hypersensitivity.
Such a role can only be fully established following identi-
fication of a receptor and effective blockade of VGF func-
tion in sensory pathways.
Methods
All animal procedures were carried out on Sprague Daw-
ley rats and performed in accordance with the Animals
(Scientific Procedures) Act 1986.
Spared Nerve Injury (SNI) was carried out in adult rats
under 2–3% halothane/O2 anesthesia [17]. The tibial and
common peroneal branches of the sciatic nerve were
tightly ligated with 5/0 silk and axotomised, leaving only
the sural nerve intact. Cut ends of the sciatic nerve were
dipped in 2% True Blue (Sigma) for 3 min and left for 7–
21 days for retrograde labeling.
In situ hybridization was performed on frozen transverse
sections of spinal cord (10 μm) as described previously
[21] using complementary and specific rat VGF mRNA oli-
gonucleotides (SigmaGenosys, UK). The oligonucleotides
were 3' end-labeled with deoxyadenosine % Warning:
EPS-printer was not specified – α [35S]-triphosphate (spe-
cific activity <1250 Ci/mol; DuPont NEN) using terminal
deoxynucleotidyl transferase (Promega, UK). Specificity
controls were (1) pretreating sections with RNase A (1
mg/ml; Sigma, Poole, UK) for 1 hr before hybridization
and (2) coincubation of the35S-labeled oligonucleotide in
the hybridization medium with a 100-fold excess of unla-
beled oligonucleotide.
Immunohistochemical staining was performed on 40 μm
free-floating cryosections of L4/L5 spinal cord. For VGF,
the sections were blocked for 1 hr in TTBS (0.05 M Tris
saline, pH7.4/0.3% Triton-X100) containing 3% normal
rabbit serum (NRS) at room temperature and incubated at
4°C for 72 hr with goat α-VGF (G17, Santa Cruz, CA)
diluted 1:5000 in TTBS. Followed after three 10 min
washes in 0.1 M phosphate buffer by a 90 min incubation
at room temperature with biotinylated rabbit anti-goat
secondary antibody (Vector Laboratories, Burlingame,
CA) diluted 1:200 in TTBS. A further three washes in 0.1
M phosphate buffer were followed by a 60 min incuba-
tion at room temperature with Avidin Biotin complex (2.5
μl A, 2.5 μl B per ml of TTBS). Signal was amplified using
a tyramide amplification protocol. Controls were carried
out without the primary antibody. In addition, 3 inde-
pendent primary antibodies to VGF were used. VGF (R15)
which recognises the C-terminus of VGF, VGF (D20)
which recognises the N-terminal of VGF and VGF (G17)
which also recognises the N-terminus. All three antibodies
showed the same clear and consistent increase in staining
in the DRG and dorsal horn following SNI despite being
raised to three separate VGF epitopes. Ultimately, VGF
(G17) was selected as the staining was the clearest.
Sections were double labeled for neuronal nuclei (mouse
anti-NeuN antibody (Chemicon, CA) 1:5000), calcitonin
gene regulated polypeptide (rabbit anti CGRP antibody
(Chemicon, CA) 1:4000), ionized binding calcium adap-
tor molecule-1 (rabbit anti-iba-1 (Wako, Japan) 1:2000),
isolectin B4 ((Sigma) 1:200), 5 HT (monoclonal rat anti-
serotonin, (Chemicon, CA)1:75).
Quantitative real-time PCR (RT-PCR) was performed using
the SYBR green detection system with primer sets
designed on Primer Express (Applied Biosystems, UK).
Specific PCR product amplification was confirmed using
dissociation protocol. Transcript regulation was deter-
mined using the relative standard curve method per man-
ufacturers' instructions. Relative loading was determined
prior to RT-PCR with RNA spectrophotometry followed
by gel electrophoresis and post RT-PCR by amplification
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
For each time point 4 samples of pooled tissue from 2 rats
were analyzed.Molecular Pain 2008, 4:62 http://www.molecularpain.com/content/4/1/62
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Behavioural testing
Flexion withdrawal reflex thresholds to punctate mechan-
ical stimulation of the plantar surface of the hindpaw were
established in naïve adult rats using von Frey filaments
(VF) (Stoelting, Woodvale, Il) applied sequentially to the
plantar surface of the hind paw 10 times at one second
intervals. Threshold was defined as the VF filament caus-
ing paw 50% withdrawal. Cold responses were measured
by placing a drop of acetone on the plantar of the paw and
recording the number of seconds that the paw was with-
drawn over the following 20 seconds. Rats were tested one
day prior to intrathecal injections to establish baseline
sensitivity and again immediately before anaesthetising
for intrathecal injection with TLQP-62 (C-terminal 62
amino acid rat VGF-derived peptide) or vehicle. Mechani-
cal and cold sensitivity were then tested 30 min after
application and every 15 minutes for four hours Intrathe-
cal (10 μl of drug or saline) injections were performed at
the L4–5 level in anesthetized rats (2–3 % halothane/O2)
using a 10 μl 26 G Hamilton syringe. The experimenter
was blind to the contents of the syringe and only one sen-
sory modality was tested per rat.
Single unit extracellular electrophysiological recordings were
carried out in the L4–5 dorsal horn of naïve adult rats
using standard in vivo recording techniques [22]. Rats
were anesthetized with isoflurane (4% in O2 at 400 ml/
min for induction, 2.5% at 200 ml/min for maintenance).
Single spikes with cutaneous receptive fields on the hind-
paw were recorded throughout the depth of the dorsal
horn and analysed using Chart software (AD Instruments,
UK). Spontaneous activity was recorded for one minute
followed by 3 brush stimuli and 3 pinch stimuli (1.5 sec
duration each at 30 secs intervals). A single drop of ace-
tone was the applied to the receptive field and responses
recorded for 30 seconds. Following baseline recording, 20
ul of TLQP-62 (50 nM) in saline was applied directly onto
the exposed spinal cord and stimuli were repeated at 5
and 10 minutes post drug application and every ten min-
utes thereafter for 60–120 minutes.
Whole cell patch recording in spinal cord slices
Superficial dorsal horn neurons were patched at room
temperature in 400 μm lumbar sagittal slices in 21 day old
naïve rats [23]. Pipette resistances ranged from 3–5 MΩ,
seal resistances were > 1 GΩ and electrodes were filled
with (in mM): 130 K-gluconate, 10 KCl, 0.1 CaCl2,1
EGTA, 10 HEPES, 2 MgATP (pH 7.2, 300–305 mosm).
Superficial dorsal horn neurons were visualized with IR-
DIC, and voltage clamp recordings of whole-cell currents
were obtained using a Multiclamp 700A amplifier (Axon
Instruments, CA). Spontaneous excitatory post-synaptic
potentials (sEPSCs) were observed at a holding potential
of -70 mV and baseline activity was established for at least
5 min before drug application. TLQP62 (50 nM in aCSF)
was bath applied for up to 30 minutes and its effects on
sEPSC amplitude and frequency analysed off-line.
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Additional file 1
Origins of terminal staining of VGF in the lumbar spinal cord. A. Immu-
nohistochemistry of VGF (left) and CGRP (right) in the L4 spinal cord 
following unilateral L3–5 dorsal rhizotomy 5 days earlier. Ipsilateral 
CGRP depletion indicates total loss of primary afferent input. VGF stain-
ing in the region is decreased but not totally depleted (arrow). B. VGF 
(left) and 5 HT (right) immunostaining in L4 spinal cord following uni-
lateral lesion of the dorsolateral funiculus at upper thoracic level 5 days 
earlier. Ipsilateral 5-HT depletion indicates loss of descending brainstem 
terminals, while VGF is only partially diminished (arrow). C Retrograde 
labeling of projection neurones in the rostroventral medulla, using bilat-
eral True blue (2%) injection into the L4/5 spinal cord under anaesthetic, 
5 days earlier (red), demonstrates expression of VGF in brainstem 
descending projection neurones. True blue:red. VGF:green. Double 
labeled: orange.
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